Asli Arslan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Asli Arslan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Gulhadiye Avcu
Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Ege University, İzmir, Turkey
7 shared publications - Coskun Ekemen
Division of Infectious Diseases, Department of Pediatrics, Medical School of Ege University, 35100 Izmir, Turkey
6 shared publications - Zumrut Sahbudak Bal
Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Ege University, İzmir, Turkey
6 shared publications - Emine Cigdem Ozer
Division of Infectious Diseases, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Turkey
5 shared publications - Amra Adrovic
Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa
1 shared publication - Ayse Ayzit Kilinc
Department of Pediatric Pulmonology, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Türkiye
1 shared publication
Latest Publications
- 21 April 2026
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 60 (2) , 245-257
Pulmoner ve Hepatik Tutulumu Olan Pediatrik Alveoler Ekinokokkoz ve Literatür Derlemesi: Nadir Bir Olgu
Alveolar echinococcosis (AE) caused by Echinococcus multilocularis, is a rare but potentially fatal zoonotic infection. AE most commonly presents with multiple cysts in the liver, may spread to other organs through infiltration or metastasis and can mimic malignancy with fatal consequences if not diagnosed early. Its occurrence in childhood is extremely rare and simultaneous hepatic and pulmonary involvement has been reported only in a few cases. This report aimed to discuss a pediatric AE case with concurrent hepatic and pulmonary involvement, initially misdiagnosed as malignancy, in the light of current literature. The presenting complaints, physical examination findings, diagnostic methods, treatment and follow-up results of a pediatric AE case with hepatic and pulmonary involvement were documented and pediatric AE cases available in the literature were reviewed. A 10-year-old boy presented with a fivemonth history of intermittent fever and weight loss. At admission, multiple cystic lesions were detected in the liver parenchyma, along with widespread cystic foci in both lungs. Laboratory tests revealed marked eosinophilia (44.5%), and E.multilocularis serology (IgG, IHA) together with Western blot (Em70, Em90 positivity) confirmed the diagnosis. According to the "parasitic mass in the liver, neighboring organs involvement and metastasis" classification; the case was staged as P4N0M1. Since surgical resection was not feasible, continuous albendazole therapy (15 mg/kg/day) was initiated. After one year of follow-up, significant radiological regression was observed, without new lesion development or treatment-related toxicity. Pediatric AE with multi-organ involvement may mimic malignancy and cause diagnostic delays. Early diagnosis and appropriate antiparasitic therapy can achieve favorable outcomes even when surgery is not feasible. However, the prolonged duration of therapy and the lack of a well-defined treatment endpoint pose significant challenges in terms of monitoring and potential toxicity. More clinical data are needed to establish optimal treatment duration and follow-up protocols in children.
- 21 April 2026
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 60 (2) , 245-257
Pulmoner ve Hepatik Tutulumu Olan Pediatrik Alveoler Ekinokokkoz ve Literatür Derlemesi: Nadir Bir Olgu
Alveolar echinococcosis (AE) caused by Echinococcus multilocularis, is a rare but potentially fatal zoonotic infection. AE most commonly presents with multiple cysts in the liver, may spread to other organs through infiltration or metastasis and can mimic malignancy with fatal consequences if not diagnosed early. Its occurrence in childhood is extremely rare and simultaneous hepatic and pulmonary involvement has been reported only in a few cases. This report aimed to discuss a pediatric AE case with concurrent hepatic and pulmonary involvement, initially misdiagnosed as malignancy, in the light of current literature. The presenting complaints, physical examination findings, diagnostic methods, treatment and follow-up results of a pediatric AE case with hepatic and pulmonary involvement were documented and pediatric AE cases available in the literature were reviewed. A 10-year-old boy presented with a fivemonth history of intermittent fever and weight loss. At admission, multiple cystic lesions were detected in the liver parenchyma, along with widespread cystic foci in both lungs. Laboratory tests revealed marked eosinophilia (44.5%), and E.multilocularis serology (IgG, IHA) together with Western blot (Em70, Em90 positivity) confirmed the diagnosis. According to the "parasitic mass in the liver, neighboring organs involvement and metastasis" classification; the case was staged as P4N0M1. Since surgical resection was not feasible, continuous albendazole therapy (15 mg/kg/day) was initiated. After one year of follow-up, significant radiological regression was observed, without new lesion development or treatment-related toxicity. Pediatric AE with multi-organ involvement may mimic malignancy and cause diagnostic delays. Early diagnosis and appropriate antiparasitic therapy can achieve favorable outcomes even when surgery is not feasible. However, the prolonged duration of therapy and the lack of a well-defined treatment endpoint pose significant challenges in terms of monitoring and potential toxicity. More clinical data are needed to establish optimal treatment duration and follow-up protocols in children.
- 17 December 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (4) , e150-e151
When Recurrent Otitis Turns Dangerous: Skull Base Osteomyelitis in an Immunocompetent Child
- 17 December 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (4) , e150-e151
When Recurrent Otitis Turns Dangerous: Skull Base Osteomyelitis in an Immunocompetent Child
- Open Access
- 29 September 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (6) , 685-687
Influenza A as a Potential Mimic of Central Nervous System Infections in Pediatric Patients
Cite this article as: Avcu G, Ekemen C, Arslan A, Ozer EC, Sahbudak Bal Z. Influenza A as a potential mimic of central nervous system infections in pediatric patients. Turk Arch Pediatr. 2025;60(6):685-687.
- 29 September 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (6) , 685-687
Open AccessInfluenza A as a Potential Mimic of Central Nervous System Infections in Pediatric Patients
Cite this article as: Avcu G, Ekemen C, Arslan A, Ozer EC, Sahbudak Bal Z. Influenza A as a potential mimic of central nervous system infections in pediatric patients. Turk Arch Pediatr. 2025;60(6):685-687.
- 25 August 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (12) , e475-e476
Endobronchial Tuberculosis With Cavitation in Early Infancy: A Diagnostic Challenge
- 25 August 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (12) , e475-e476
Endobronchial Tuberculosis With Cavitation in Early Infancy: A Diagnostic Challenge
- Open Access
- 28 July 2025
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 19 (07) , 1046-1054
Tigecycline therapy for multidrug-resistant bacteria: is it the right choice for pediatric patients
Introduction: The incidence of infections caused by multidrug-resistant pathogens is increasing worldwide, resulting in significant morbidity and mortality. Tigecycline has become a good option because it has a broad spectrum of antibacterial activity. This study aimed to reveal the clinical, microbiological, and laboratory outcomes of hospitalized children treated with tigecycline. Methodology: We retrospectively collected the medical records of the hospitalized pediatric patients treated with tigecycline from April 1, 2018, to Apr 30, 2023, at Ege University Children's Hospital. Demographic features and clinical and laboratory findings were evaluated to determine the efficacy and safety of tigecycline therapy. Results: Sixty-seven patients (65.7% male) with a median age of 6 years (2.5 months-17.5 years) were included. There was an underlying condition in 83.5% of the patients, and 55.2% were immunosuppressed. The most common infections were; lower respiratory tract infections (29.8%), intra-abdominal infections (20.9%), bloodstream infections (17.9%), and soft tissue infections (13.4%), respectively. Acinetobacter spp. (28.4%) was the most isolated microorganism, followed by Klebsiella spp. (19.4%) and Enterococcus spp. (14.9%). Tigecycline was used as a targeted treatment in 76.1% of the patients and was often used as a combination therapy (80.6%) with a median duration of 12 days (range, 2-60 days). Clinical response was achieved in 65.6% of patients, microbiologic response in 62.6%, and treatment failure in 34.3%. No major adverse events were noted during the therapy. Conclusions: Tigecycline, which was mostly preferred in combination therapy, had high clinical response and microbiologic eradication rates, but these rates varied according to infection sites and microorganism species.
- 28 July 2025
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 19 (07) , 1046-1054
Open AccessTigecycline therapy for multidrug-resistant bacteria: is it the right choice for pediatric patients
Introduction: The incidence of infections caused by multidrug-resistant pathogens is increasing worldwide, resulting in significant morbidity and mortality. Tigecycline has become a good option because it has a broad spectrum of antibacterial activity. This study aimed to reveal the clinical, microbiological, and laboratory outcomes of hospitalized children treated with tigecycline. Methodology: We retrospectively collected the medical records of the hospitalized pediatric patients treated with tigecycline from April 1, 2018, to Apr 30, 2023, at Ege University Children's Hospital. Demographic features and clinical and laboratory findings were evaluated to determine the efficacy and safety of tigecycline therapy. Results: Sixty-seven patients (65.7% male) with a median age of 6 years (2.5 months-17.5 years) were included. There was an underlying condition in 83.5% of the patients, and 55.2% were immunosuppressed. The most common infections were; lower respiratory tract infections (29.8%), intra-abdominal infections (20.9%), bloodstream infections (17.9%), and soft tissue infections (13.4%), respectively. Acinetobacter spp. (28.4%) was the most isolated microorganism, followed by Klebsiella spp. (19.4%) and Enterococcus spp. (14.9%). Tigecycline was used as a targeted treatment in 76.1% of the patients and was often used as a combination therapy (80.6%) with a median duration of 12 days (range, 2-60 days). Clinical response was achieved in 65.6% of patients, microbiologic response in 62.6%, and treatment failure in 34.3%. No major adverse events were noted during the therapy. Conclusions: Tigecycline, which was mostly preferred in combination therapy, had high clinical response and microbiologic eradication rates, but these rates varied according to infection sites and microorganism species.
- Open Access
- 6 July 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (3) , 433-439
Successful viral suppression in a two-year-old child with human immunodeficiency virus infection treated with bictegravir/emtricitabine/tenofovir alafenamide
Background. Adherence to antiretroviral therapy (ART) is a major challenge in pediatric human immunodeficiency virus (HIV) management, especially in young children due to medication formulation, administration difficulties, and psychosocial barriers. Single-tablet regimens (STRs) have been shown to improve adherence and viral suppression in adults and adolescents, yet their use in younger children remains limited. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is an STR with a high genetic barrier to resistance, making it a promising option for pediatric patients with adherence difficulties. Case Presentation. We report a case of a 2-year-old girl with perinatally acquired HIV who experienced persistent viremia despite multiple ART regimens. The mother received zidovudine prophylaxis during delivery, and the infant was started on zidovudine (AZT) prophylaxis on the first day of life. The patient’s ART history included AZT monotherapy at birth, followed by combination therapy with lamivudine (3TC), lopinavir/ritonavir (LPV/r), and later tenofovir/emtricitabine (TDF/FTC) with dolutegravir (DTG). Despite these regimens, poor adherence related to medication administration difficulties and caregiver challenges contributed to persistent viremia. A multidisciplinary team approach was implemented to address adherence barriers. Given the patient’s ongoing virological failure and resistance mutations (L76V and V179E), off-label use of BIC/FTC/TAF (50mg/200mg/25mg) was approved. The dosage was adjusted based on weight, and medication administration was closely monitored. Within one month of treatment, HIV RNA levels significantly declined from 1,800,000 to 207 copies/mL. Viral suppression was maintained over subsequent three-month intervals, with HIV RNA levels of 35, 40, and 43 copies/mL, alongside immune recovery as indicated by increased CD4 counts. Conclusion. The successful off-label use of BIC/FTC/TAF in a treatment-refractory pediatric HIV case highlights its potential efficacy in young patients facing adherence challenges. Its high genetic barrier to resistance and favorable tolerability make it a promising option when standard therapies fail. Further research is needed to optimize pediatric ART strategies and expand access to STRs globally.
- 6 July 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (3) , 433-439
Open AccessSuccessful viral suppression in a two-year-old child with human immunodeficiency virus infection treated with bictegravir/emtricitabine/tenofovir alafenamide
Background. Adherence to antiretroviral therapy (ART) is a major challenge in pediatric human immunodeficiency virus (HIV) management, especially in young children due to medication formulation, administration difficulties, and psychosocial barriers. Single-tablet regimens (STRs) have been shown to improve adherence and viral suppression in adults and adolescents, yet their use in younger children remains limited. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is an STR with a high genetic barrier to resistance, making it a promising option for pediatric patients with adherence difficulties. Case Presentation. We report a case of a 2-year-old girl with perinatally acquired HIV who experienced persistent viremia despite multiple ART regimens. The mother received zidovudine prophylaxis during delivery, and the infant was started on zidovudine (AZT) prophylaxis on the first day of life. The patient’s ART history included AZT monotherapy at birth, followed by combination therapy with lamivudine (3TC), lopinavir/ritonavir (LPV/r), and later tenofovir/emtricitabine (TDF/FTC) with dolutegravir (DTG). Despite these regimens, poor adherence related to medication administration difficulties and caregiver challenges contributed to persistent viremia. A multidisciplinary team approach was implemented to address adherence barriers. Given the patient’s ongoing virological failure and resistance mutations (L76V and V179E), off-label use of BIC/FTC/TAF (50mg/200mg/25mg) was approved. The dosage was adjusted based on weight, and medication administration was closely monitored. Within one month of treatment, HIV RNA levels significantly declined from 1,800,000 to 207 copies/mL. Viral suppression was maintained over subsequent three-month intervals, with HIV RNA levels of 35, 40, and 43 copies/mL, alongside immune recovery as indicated by increased CD4 counts. Conclusion. The successful off-label use of BIC/FTC/TAF in a treatment-refractory pediatric HIV case highlights its potential efficacy in young patients facing adherence challenges. Its high genetic barrier to resistance and favorable tolerability make it a promising option when standard therapies fail. Further research is needed to optimize pediatric ART strategies and expand access to STRs globally.
- 21 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (6) , e234-e235
A Pediatric Case of Mastoiditis, Meningitis, Ventriculitis and Sinus Venous Thrombosis Due to Streptococcus pneumoniae During Tocilizumab Therapy
- 21 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (6) , e234-e235
A Pediatric Case of Mastoiditis, Meningitis, Ventriculitis and Sinus Venous Thrombosis Due to Streptococcus pneumoniae During Tocilizumab Therapy
- 29 November 2019
- Published by Springer Nature in Rheumatology International
- Vol. 40 (10) , 1701-1706
Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study
Krebs von den Lungen-6 (KL-6) has been described as a promising biomarker in the diagnosis and determining the severity of interstitial lung disease in adults with connective tissue disease. This study was performed to determine whether the serum KL-6 level is useful as a biomarker for detecting the interstitial lung disease (ILD) in pediatric cases of connective tissue disease (CTD). In total, 88 patients [36 patients with systemic juvenile idiopathic arthritis (sJIA), 27 patients with juvenile systemic lupus erythematosus (JSLE), 14 patients with juvenile dermatomyositis (JDM), and 11 patients with juvenile systemic sclerosis (JSSc)] and 68 healthy controls were included in this study. Age, sex, and duration of CTD and ILD (if any) were recorded. Blood samples from all the patients and controls were examined by ELISA. Eleven of the 88 patients with CTD (12.5%) had ILD and all of them were symptomatic. Subgroup analysis indicated that eight patients had JSSc, two had JSLE, and one had systemic JIA. The median serum KL-6 level was 1450.5 U/mL (interquartile range (IQR) 742.9–2603.2) in the CTD with ILD group, 415.9 U/mL (IQR 233.4–748.4) in the CTD without ILD group, and 465.9 U/mL (IQR 273.6–1036) in the control group. KL-6 levels were significantly higher in the CTD with ILD group than the CTD without ILD group and the control group (p = 0.003). At a cut-off of 712.5 U/ml identified by ROC curve, serum KL-6 yielded a sensitivity of 81% and specificity of 72% for CTD with ILD group. There was no significant difference in serum KL-6 level among the disease subgroups (sJIA, JSLE, JSSc, JDM), in either the CTD with ILD group or the CTD without ILD group (p > 0.05). In conclusion, KL-6 is a useful biomarker of CTD with ILD in pediatric patients.
- 29 November 2019
- Published by Springer Nature in Rheumatology International
- Vol. 40 (10) , 1701-1706
Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study
Krebs von den Lungen-6 (KL-6) has been described as a promising biomarker in the diagnosis and determining the severity of interstitial lung disease in adults with connective tissue disease. This study was performed to determine whether the serum KL-6 level is useful as a biomarker for detecting the interstitial lung disease (ILD) in pediatric cases of connective tissue disease (CTD). In total, 88 patients [36 patients with systemic juvenile idiopathic arthritis (sJIA), 27 patients with juvenile systemic lupus erythematosus (JSLE), 14 patients with juvenile dermatomyositis (JDM), and 11 patients with juvenile systemic sclerosis (JSSc)] and 68 healthy controls were included in this study. Age, sex, and duration of CTD and ILD (if any) were recorded. Blood samples from all the patients and controls were examined by ELISA. Eleven of the 88 patients with CTD (12.5%) had ILD and all of them were symptomatic. Subgroup analysis indicated that eight patients had JSSc, two had JSLE, and one had systemic JIA. The median serum KL-6 level was 1450.5 U/mL (interquartile range (IQR) 742.9–2603.2) in the CTD with ILD group, 415.9 U/mL (IQR 233.4–748.4) in the CTD without ILD group, and 465.9 U/mL (IQR 273.6–1036) in the control group. KL-6 levels were significantly higher in the CTD with ILD group than the CTD without ILD group and the control group (p = 0.003). At a cut-off of 712.5 U/ml identified by ROC curve, serum KL-6 yielded a sensitivity of 81% and specificity of 72% for CTD with ILD group. There was no significant difference in serum KL-6 level among the disease subgroups (sJIA, JSLE, JSSc, JDM), in either the CTD with ILD group or the CTD without ILD group (p > 0.05). In conclusion, KL-6 is a useful biomarker of CTD with ILD in pediatric patients.